Target intelligence / Profile preview

MUS81-EME1 endonuclease complex (MUS81-EME1)

Target
MUS81-EME1
Molecular classification
Enzyme, Endonuclease, Structure-specific endonuclease, XPF family nuclease
01

Overview

The MUS81-EME1 endonuclease complex is a structure-specific nuclease essential for processing DNA intermediates during replication and repair. It consists of the catalytic subunit MUS81 and the regulatory subunit EME1, which together recognize and cleave branched DNA structures like Holliday junctions and stalled replication forks (UniProt Q96NY9, Q8N163). This activity is particularly vital during the late G2 and M phases of the cell cycle, where it facilitates the resolution of recombination intermediates and supports mitotic DNA synthesis (MiDAS) at difficult-to-replicate regions (PubMed: 26371554). In the context of oncology, the complex is a key target for synthetic lethality strategies. Cancer cells with deficiencies in the homologous recombination pathway, such as those with BRCA1 or BRCA2 mutations, become highly dependent on MUS81-EME1 for survival (PubMed: 30639243). Consequently, small molecule inhibitors of MUS81 are being explored to selectively induce DNA damage and apoptosis in these vulnerable tumor cells while sparing healthy tissue. Beyond direct inhibition, the complex is also studied for its role in mediating resistance to certain chemotherapeutic agents that induce replication stress.

Other names
MUS81-EME1 structure-specific endonucleaseEME1-MUS81 complexMMS4-MUS81 (yeast ortholog)Crossover junction endonuclease MUS81 complex
02

Mechanism of action

Inhibition of the structure-specific endonuclease activity to prevent the resolution of stalled replication forks and recombination intermediates, inducing synthetic lethality in DNA repair-deficient cells.

03

Biological functions

DNA repairHomologous recombinationResolution of Holliday junctionsMitotic DNA synthesis (MiDAS)DNA replication stress responseMaintenance of genomic stability
04

Disease associations

CancerBreast cancerOvarian cancerProstate cancerFanconi anemia pathway-related disorders
05

Safety considerations

Potential for systemic genomic instabilityRisk of secondary malignanciesHematological toxicityOff-target effects on related nucleases
06

Interacting drugs

MUS81 inhibitors (preclinical)

1 more in the full profile.

07

Biomarkers

BRCA1 mutationBRCA2 mutationATM deficiencyCCNE1 amplificationDNA replication stress markers

Beyond the preview

Go deeper on MUS81-EME1 endonuclease complex (MUS81-EME1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUS81-EME1 endonuclease complex (MUS81-EME1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call